Literature DB >> 3101896

Diabetogenic effect of cyclosporin.

J J Bending, C S Ogg, G C Viberti.   

Abstract

A young woman given a renal allograft for polycystic kidney disease developed insulin dependent diabetes mellitus 25 days after transplantation. There was no family history of diabetes, plasma glucose concentrations had been normal at presentation and on five subsequent occasions, and at no time were islet cell antibodies detectable. Plasma C peptide concentrations, however, were greatly suppressed after transplantation and remained so for up to six months. The immunosuppressive regimen had included cyclosporin A, which had been difficult to regulate and caused definite signs of toxicity in the patient. By virtue of its reported toxicity for beta cells and the reversal of the diabetes several months after the dose was reduced cyclosporin was incriminated as the probable causative agent. Dose related beta cell toxicity of cyclosporin A may be a risk in recipients of this drug and warrants careful monitoring of drug and glucose concentrations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101896      PMCID: PMC1245410          DOI: 10.1136/bmj.294.6569.401

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  4 in total

Review 1.  A role for cyclosporin A in the treatment of insulin-dependent diabetes mellitus?

Authors:  J Nerup; K Bendtzen; T Mandrup-Poulsen
Journal:  Diabet Med       Date:  1985-11       Impact factor: 4.359

2.  Correlation between insulin clearance and insulin responsiveness: studies in normal, obese, hyperthyroid, and Cushing's syndrome patients.

Authors:  P Cohen; N Barzilai; D Barzilai; E Karnieli
Journal:  Metabolism       Date:  1986-08       Impact factor: 8.694

3.  Direct effects of cyclosporin A on human pancreatic beta-cells.

Authors:  J H Nielsen; T Mandrup-Poulsen; J Nerup
Journal:  Diabetes       Date:  1986-09       Impact factor: 9.461

4.  Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.

Authors:  R A Rizza; L J Mandarino; J E Gerich
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

  4 in total
  3 in total

Review 1.  Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management.

Authors:  David Langsford; Karen Dwyer
Journal:  World J Diabetes       Date:  2015-08-25

2.  Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production.

Authors:  M Shenoy; B MacPherson; P Christadoss
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

3.  Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients.

Authors:  Alireza Boloori; Soroush Saghafian; Harini A Chakkera; Curtiss B Cook
Journal:  PLoS One       Date:  2015-11-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.